卡铂-紫杉醇对比卡铂-紫杉醇-贝伐珠单抗治疗晚期或复发性子宫内膜癌:MITO END-2随机II期试验
在晚期(FIGO III-IV期)或复发性子宫内膜癌患者中开展的II期随机试验显示,卡铂-紫杉醇联合贝伐珠单抗(15 mg/kg,化疗期间及维持至疾病进展或不可耐受毒性)对比单纯卡铂-紫杉醇,无进展生存期(10.5 vs 13.7个月,HR 0.84,p=0.43)、总缓解率(53.1% vs 74.4%)和总生存期(29.7 vs 40.0个月,HR 0.71,p=0.24)在贝伐珠单抗组呈非显著升高。贝伐珠单抗组6个月疾病控制率显著升高(70.4% vs 90.7%),但心血管事件更常见。
要点
- 贝伐珠单抗联合化疗未显著延长晚期/复发性子宫内膜癌患者的无进展生存期(10.5 vs 13.7个月,HR 0.84,p=0.43)。
- 贝伐珠单抗组6个月疾病控制率显著升高(70.4% vs 90.7%)。
- 贝伐珠单抗组心血管事件更常见:新发≥2级高血压21% vs 0%,≥2级血栓栓塞事件11% vs 2%。
核心结论
- 贝伐珠单抗联合化疗治疗晚期/复发性子宫内膜癌在MITO END-2试验中未能显著增加无进展生存期。
- 这些初步数据提示该抗血管生成药物有一定疗效,值得在更大规模且分子特征更明确的人群中进一步探索。
研究设计与样本
- II期随机试验,纳入晚期(FIGO III-IV期)或复发性子宫内膜癌患者108例。
- 随机接受卡铂-紫杉醇标准剂量6-8周期 vs 卡铂-紫杉醇联合贝伐珠单抗15 mg/kg(化疗期间联合及维持至疾病进展或不可耐受毒性)。
- 主要终点为无进展生存期(PFS)。
主要发现
- 无进展生存期:贝伐珠单抗组13.7个月 vs 标准治疗组10.5个月(HR 0.84,p=0.43),差异未达统计学显著。
- 总缓解率:贝伐珠单抗组74.4% vs 标准治疗组53.1%。
- 总生存期:贝伐珠单抗组40.0个月 vs 标准治疗组29.7个月(HR 0.71,p=0.24),差异未达统计学显著。
- 探索性Breslow检验显示贝伐珠单抗组PFS增加具有显著性。
- 6个月疾病控制率:贝伐珠单抗组90.7% vs 标准治疗组70.4%,贝伐珠单抗组显著升高。
关键数值与推荐
- 贝伐珠单抗剂量为15 mg/kg,与化疗联合并维持至疾病进展或不可耐受毒性。
- 卡铂-紫杉醇标准剂量给药6-8周期。
- 主要终点无进展生存期:贝伐珠单抗组13.7个月 vs 标准治疗组10.5个月(HR 0.84,p=0.43)。
- 总生存期:贝伐珠单抗组40.0个月 vs 标准治疗组29.7个月(HR 0.71,p=0.24)。
- 6个月疾病控制率:贝伐珠单抗组90.7% vs 标准治疗组70.4%。
临床怎么用
- 原文未据此给出推荐。
- 作者认为这些初步数据提示贝伐珠单抗有一定疗效,值得在更大规模且分子特征更明确的人群中进一步探索。
局限性
- 原文为II期试验,样本量为108例。
- 原文结论称这些为初步数据,值得在更大规模且分子特征更明确的人群中进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical data reported Bevacizumab effectiveness in EC both as single agent and in combination with chemotherapy. METHODS: In a phase II trial, patients with advanced (FIGO stage III-IV) or recurrent EC were randomized to receive Carboplatin-Paclitaxel standard dose for 6-8 cycles vs Carboplatin-Paclitaxel and Bevacizumab 15 mg/kg in combination with chemotherapy and maintenance until disease progression or unacceptable toxicity. The primary endpoint was progression free survival (PFS). RESULTS: 108 patients were randomized; PFS (10.5 vs 13.7 months, HR 0.84 p = 0.43), overall response rate (ORR 53.1% vs 74.4%) and overall survival (OS) (29.7 vs 40.0 months, HR 0.71 p = 0.24) resulted in a non-significant increase in Bevacizumab treated patients. The PFS increase became significant when an exploratory analysis with the Breslow test was used. Moreover, patients treated with Bevacizumab experienced a significant increase in 6-month disease control rate (70.4% vs 90.7%). Cardiovascular events were more frequent in the experimental arm ("de novo" grade ≥2 hypertension 21% vs 0% and grade ≥2 thromboembolic events 11% vs 2% in the Bevacizumab vs standard treatment arm, respectively). CONCLUSIONS: Bevacizumab combined with chemotherapy in the treatment of advanced/recurrent EC failed to demonstrate a significant increase in PFS in the MITO END-2 trial. Nevertheless, these preliminary data suggests some effectiveness of the antiangiogenic agent which merits further exploration in a larger population with a better molecular characterization.
引用
- Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. Gynecol Oncol. 2019. PMID: 31677820. doi:10.1016/j.ygyno.2019.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。